Belite Bio (BLTE) Scheduled to Post Quarterly Earnings on Tuesday

Belite Bio (NASDAQ:BLTE) will be announcing its earnings results after the market closes on Tuesday, November 12th. Analysts expect Belite Bio to post earnings of ($0.30) per share for the quarter. Individual that wish to register for the company’s earnings conference call can do so using this link.

Belite Bio (NASDAQ:BLTE) last released its quarterly earnings data on Friday, August 9th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.03). On average, analysts expect Belite Bio to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Belite Bio Trading Down 1.6 %

Shares of NASDAQ BLTE opened at $81.08 on Monday. The stock has a 50 day moving average of $55.90 and a 200-day moving average of $50.21. Belite Bio has a 12 month low of $31.00 and a 12 month high of $83.60. The company has a market capitalization of $2.48 billion, a P/E ratio of -65.92 and a beta of -1.60.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on BLTE shares. Benchmark reissued a “buy” rating and issued a $57.00 price objective on shares of Belite Bio in a research report on Tuesday, August 13th. HC Wainwright reissued a “buy” rating and issued a $60.00 price target on shares of Belite Bio in a report on Thursday, September 12th.

About Belite Bio

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company’s lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients.